Pulse nav.journalClub Tendencias Explorar Preguntas Investigadores

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors | Synapse

May 7, 2021Open Access

Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This cohort study examines the association of BRCA1 and BRCA2 with tumor mutation burden and response to immune checkpoint inhibitors.

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Zhou et al. (Fri,) studied this question.

synapsesocial.com/papers/6a0279fecd28bf9e2101d61c https://doi.org/https://doi.org/10.1001/jamanetworkopen.2021.7728

Me gusta

Guardar

Compartir

Ver artículo completo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Tumor mutational load predicts survival after immunotherapy across multiple cancer types2019 · 4,354 citations
2Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer2019 · 432 citations
3CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma2016 · 836 citations
4The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data2012 · 18,405 citations
5Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study2020 · 456 citations